Open AccessThe impact of the withdrawal of Adderall XR (long-acting mixed amphetamine salts) from the Canadian market on paediatric patients and their families
Author(s) -
Anita Cheng,
Gary Tithecott,
Wendy E Edwards,
Ian G. Johnston
Publication year - 2007
Publication title -
paediatrics and child health
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.55
H-Index - 43
eISSN - 1918-1485
pISSN - 1205-7088
DOI - 10.1093/pch/12.5.373
Subject(s) - anger , medicine , psychiatry , recall , family medicine , pediatrics , psychology , cognitive psychology
Adderall XR (Shire BioChem Inc, Canada), a medication used to treat attention deficit hyperactivity disorder, was withdrawn from the Canadian market in February 2005 due to concerns of possible cardiotoxicity and cerebral vascular events among a small number of individuals who had taken the medication.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom